Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (80)

« Back to Publications

Acute Plasmodium yoelii 17XNL Infection During BCG Vaccination Limits T Cell Responses and Mycobacterial Growth Inhibition.

Tangie E. et al, (2025), Immunology, 176, 373 - 384

Functional and phenotypic characterization of peripheral blood mononuclear cells from tuberculosis patients in Southern Thailand

Sone Oo P. et al, (2025), Frontiers in Immunology, 16

Tuberculosis in patients with systemic lupus erythematosus

Ongarj J. et al, (2025), Frontiers in Immunology, 16

MetE: a promising protective antigen for tuberculosis vaccine development

Almujri SS. et al, (2025), Frontiers in Immunology, 16

Early mucosal responses following a randomised controlled human inhaled infection with attenuated Mycobacterium bovis BCG

Marshall JL. et al, (2025), Nature Communications, 16

Immune mechanisms mediating the heterologous effects of BCG vaccination: a systematic review

Torracinta L. et al, (2025), Frontiers in Immunology, 16

Workshop report: One Health challenges and knowledge gaps in the control of intracellular infections with a focus on tuberculosis and leishmaniasis

Miller M. et al, (2025), Vaccine, 53, 126929 - 126929

Intravenous BCG vaccination in non-human primates induces superior serum antibody titers with enhanced avidity and opsonizing capacity compared to the intradermal route

Peralta Alvarez MP. et al, (2024), Vaccine, 42, 126444 - 126444

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates

Peralta-Álvarez MP. et al, (2024), npj Vaccines, 9

Evaluation of immune profiles associated with control of mycobacterial growth in systemic lupus erythematosus (SLE) patients.

Ongarj J. et al, (2024), Tuberculosis (Edinburgh, Scotland), 148

Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK: a dose-escalation, randomised, controlled, phase 1 trial

Satti I. et al, (2024), The Lancet Infectious Diseases, 24, 909 - 921

Safety, tolerability, viral kinetics, and immune correlates of protection in healthy, seropositive UK adults inoculated with SARS-CoV-2: a single-centre, open-label, phase 1 controlled human infection study

Jackson S. et al, (2024), The Lancet Microbe, 5, 655 - 668

Low-dose M.tb infection but not BCG or MTBVAC vaccination enhances heterologous antibody titres in non-human primates

Peralta Alvarez MP. et al, (2024), Frontiers in Immunology, 15

Demonstrating the utility of the ex vivo murine mycobacterial growth inhibition assay (MGIA) for high-throughput screening of tuberculosis vaccine candidates against multiple Mycobacterium tuberculosis complex strains

Painter H. et al, (2024), Tuberculosis, 146, 102494 - 102494

Development and application of the direct mycobacterial growth inhibition assay: a systematic review.

Painter H. et al, (2024), Frontiers in immunology, 15

Load More

1
2
3
4
5
6